Published in Clin Sci (Lond) on May 01, 1984
In vivo and in vitro sodium pump activity in subjects with thyrotoxic periodic paralysis. BMJ (1991) 1.66
In vivo cation transport during short-term and long-term digoxin therapy. Br J Clin Pharmacol (1986) 0.87
A study of the transport of lithium across the erythrocyte membrane in vivo and of the effects of the ion transport inhibitors digoxin and dipyridamole. Br J Clin Pharmacol (1989) 0.81
Increase in Na+/K+ pump numbers in vivo in healthy volunteers taking oral lithium carbonate and further upregulation in response to lithium in vitro. Br J Clin Pharmacol (1992) 0.75
The effect of oral salbutamol on cation transport measured in vivo in healthy volunteers. Br J Clin Pharmacol (1990) 0.75
Adverse drug reactions: definitions, diagnosis, and management. Lancet (2000) 16.12
Melioidosis: a major cause of community-acquired septicemia in northeastern Thailand. J Infect Dis (1989) 8.24
Effects of artemisinin derivatives on malaria transmissibility. Lancet (1996) 7.42
Human cerebral malaria. A quantitative ultrastructural analysis of parasitized erythrocyte sequestration. Am J Pathol (1985) 7.14
Effects of artesunate-mefloquine combination on incidence of Plasmodium falciparum malaria and mefloquine resistance in western Thailand: a prospective study. Lancet (2000) 7.06
Neurological manifestations of dengue infection. Lancet (2000) 5.69
The epidemiology of malaria in a Karen population on the western border of Thailand. Trans R Soc Trop Med Hyg (1996) 5.35
Qinghaosu. Lancet (1993) 5.25
Halofantrine versus mefloquine in treatment of multidrug-resistant falciparum malaria. Lancet (1993) 5.11
Plasmodium falciparum: in vitro studies of the pharmacodynamic properties of drugs used for the treatment of severe malaria. Exp Parasitol (1993) 4.98
Randomised double-blind placebo-controlled trial of SPf66 malaria vaccine in children in northwestern Thailand. Shoklo SPf66 Malaria Vaccine Trial Group. Lancet (1996) 4.90
Pharmacokinetics and pharmacodynamics of lumefantrine (benflumetol) in acute falciparum malaria. Antimicrob Agents Chemother (2000) 4.77
A controlled trial of artemether or quinine in Vietnamese adults with severe falciparum malaria. N Engl J Med (1996) 4.64
The pfmdr1 gene is associated with a multidrug-resistant phenotype in Plasmodium falciparum from the western border of Thailand. Antimicrob Agents Chemother (1999) 4.64
Plasmodium falciparum antimalarial drug susceptibility on the north-western border of Thailand during five years of extensive use of artesunate-mefloquine. Trans R Soc Trop Med Hyg (2000) 4.63
Quinolone-resistant Salmonella typhi in Viet Nam: molecular basis of resistance and clinical response to treatment. Clin Infect Dis (1997) 4.53
Adverse drug reactions in a hospital general medical unit meriting notification to the Committee on Safety of Medicines. Br J Clin Pharmacol (1996) 4.50
The epidemiology of severe malaria in an area of low transmission in Thailand. Trans R Soc Trop Med Hyg (1997) 4.48
Pre-referral rectal artesunate to prevent death and disability in severe malaria: a placebo-controlled trial. Lancet (2008) 4.35
Fake antimalarials in Southeast Asia are a major impediment to malaria control: multinational cross-sectional survey on the prevalence of fake antimalarials. Trop Med Int Health (2004) 4.35
Treatment of multidrug-resistant Plasmodium falciparum malaria with 3-day artesunate-mefloquine combination. J Infect Dis (1994) 4.17
Fake artesunate in southeast Asia. Lancet (2001) 3.84
Mefloquine-resistant falciparum malaria on the Thai-Burmese border. Lancet (1991) 3.72
A quantitative analysis of the microvascular sequestration of malaria parasites in the human brain. Am J Pathol (1999) 3.72
Diagnosis of adult tuberculous meningitis by use of clinical and laboratory features. Lancet (2002) 3.65
Effects of Plasmodium vivax malaria in pregnancy. Lancet (1999) 3.62
Identification of Pseudomonas pseudomallei in clinical practice: use of simple screening tests and API 20NE. J Clin Pathol (1989) 3.57
Therapeutic responses to different antimalarial drugs in vivax malaria. Antimicrob Agents Chemother (2000) 3.46
Factors contributing to anemia after uncomplicated falciparum malaria. Am J Trop Med Hyg (2001) 3.46
Artesunate/mefloquine treatment of multi-drug resistant falciparum malaria. Trans R Soc Trop Med Hyg (1998) 3.39
Studies in vivo on the relationship between brain tryptophan, brain 5-HT synthesis and hyperactivity in rats treated with a monoamine oxidase inhibitor and L-tryptophan. J Neurochem (1971) 3.34
Persistence of Plasmodium falciparum HRP-2 in successfully treated acute falciparum malaria. Trans R Soc Trop Med Hyg (2001) 3.32
Cardiac effects of antimalarial treatment with halofantrine. Lancet (1993) 3.32
The epidemiology of melioidosis in Ubon Ratchatani, northeast Thailand. Int J Epidemiol (1994) 3.23
Neurological sequelae of cerebral malaria in children. Lancet (1990) 3.11
Malaria during pregnancy in an area of unstable endemicity. Trans R Soc Trop Med Hyg (1992) 3.10
Severe hypoglycemia and hyperinsulinemia in falciparum malaria. N Engl J Med (1983) 3.07
Clinical pharmacokinetics of antimalarial drugs. Clin Pharmacokinet (1985) 3.03
Adenosine 3',5'-monophosphate as the intracellular mediator of the action of adrenocorticotropic hormone on the adrenal cortex. J Biol Chem (1967) 3.03
Quantitation of bacteria in blood of typhoid fever patients and relationship between counts and clinical features, transmissibility, and antibiotic resistance. J Clin Microbiol (1998) 3.02
Efficacy of six doses of artemether-lumefantrine (benflumetol) in multidrug-resistant Plasmodium falciparum malaria. Am J Trop Med Hyg (1999) 2.98
Risk factors for gametocyte carriage in uncomplicated falciparum malaria. Am J Trop Med Hyg (1999) 2.94
Relation of the stage of parasite development in the peripheral blood to prognosis in severe falciparum malaria. Trans R Soc Trop Med Hyg (1993) 2.90
Molecular basis of sequestration in severe and uncomplicated Plasmodium falciparum malaria: differential adhesion of infected erythrocytes to CD36 and ICAM-1. J Infect Dis (1991) 2.87
Direct in vivo assessment of microcirculatory dysfunction in severe falciparum malaria. J Infect Dis (2008) 2.77
Artemether-lumefantrine for the treatment of multidrug-resistant falciparum malaria. Trans R Soc Trop Med Hyg (2000) 2.76
Arabinose assimilation defines a nonvirulent biotype of Burkholderia pseudomallei. Infect Immun (1997) 2.72
Quinine pharmacokinetics and toxicity in cerebral and uncomplicated Falciparum malaria. Am J Med (1982) 2.71
Randomized placebo-controlled trial of continuous positive airway pressure on blood pressure in the sleep apnea-hypopnea syndrome. Am J Respir Crit Care Med (2001) 2.68
Population dynamics of untreated Plasmodium falciparum malaria within the adult human host during the expansion phase of the infection. Parasitology (2002) 2.67
Adverse effects of falciparum and vivax malaria and the safety of antimalarial treatment in early pregnancy: a population-based study. Lancet Infect Dis (2011) 2.65
Randomized comparison of artemether-benflumetol and artesunate-mefloquine in treatment of multidrug-resistant falciparum malaria. Antimicrob Agents Chemother (1998) 2.61
Relapse in melioidosis: incidence and risk factors. J Infect Dis (1993) 2.61
Antimalarial drugs reduce cytoadherence and rosetting Plasmodium falciparum. J Infect Dis (1996) 2.59
Clinical features cannot predict a diagnosis of malaria or differentiate the infecting species in children living in an area of low transmission. Trans R Soc Trop Med Hyg (1998) 2.54
Quantitative recovery of Burkholderia pseudomallei from soil in Thailand. Trans R Soc Trop Med Hyg (1996) 2.54
Mefloquine pharmacokinetic-pharmacodynamic models: implications for dosing and resistance. Antimicrob Agents Chemother (2000) 2.54
Quantitation of bacteria in bone marrow from patients with typhoid fever: relationship between counts and clinical features. J Clin Microbiol (2001) 2.53
High rate of Plasmodium vivax relapse following treatment of falciparum malaria in Thailand. Lancet (1987) 2.52
Increased platelet aggregation responses to 5-hydroxytryptamine in patients taking chlorpromazine. Br J Clin Pharmacol (1975) 2.49
The prognostic and pathophysiologic role of pro- and antiinflammatory cytokines in severe malaria. J Infect Dis (1999) 2.49
Multiple-dose activated charcoal for treatment of yellow oleander poisoning: a single-blind, randomised, placebo-controlled trial. Lancet (2003) 2.47
The antimicrobial susceptibility of Pseudomonas pseudomallei. Emergence of resistance in vitro and during treatment. J Antimicrob Chemother (1989) 2.44
Microsatellite variation, repeat array length, and population history of Plasmodium vivax. Mol Biol Evol (2006) 2.43
The pathophysiologic and prognostic significance of acidosis in severe adult malaria. Crit Care Med (2000) 2.42
The effects of dopamine and adrenaline infusions on acid-base balance and systemic haemodynamics in severe infection. Lancet (1996) 2.41
Poliomyelitis-like illness due to Japanese encephalitis virus. Lancet (1998) 2.41
Association of genetic mutations in Plasmodium vivax dhfr with resistance to sulfadoxine-pyrimethamine: geographical and clinical correlates. Antimicrob Agents Chemother (2001) 2.40
The use of selective media for the isolation of Pseudomonas pseudomallei in clinical practice. J Med Microbiol (1990) 2.39
The mechanisms of parasite clearance after antimalarial treatment of Plasmodium falciparum malaria. J Infect Dis (2000) 2.35
Semi-quantitative measurement of Plasmodium falciparum antigen PfHRP2 in blood and plasma. Trans R Soc Trop Med Hyg (1997) 2.33
Incomplete evidence: the inadequacy of databases in tracing published adverse drug reactions in clinical trials. BMC Med Res Methodol (2001) 2.33
Pharmacokinetics of quinine, chloroquine and amodiaquine. Clinical implications. Clin Pharmacokinet (1996) 2.33
Pharmacokinetic determinants of the window of selection for antimalarial drug resistance. Antimicrob Agents Chemother (2008) 2.27
Medication errors, worse than a crime. Lancet (2000) 2.24
Predictors of mefloquine treatment failure: a prospective study of 1590 patients with uncomplicated falciparum malaria. Trans R Soc Trop Med Hyg (1996) 2.24
A prescription for better prescribing. Br J Clin Pharmacol (2006) 2.24
Mefloquine prophylaxis prevents malaria during pregnancy: a double-blind, placebo-controlled study. J Infect Dis (1994) 2.23
Population pharmacokinetics of piperaquine after two different treatment regimens with dihydroartemisinin-piperaquine in patients with Plasmodium falciparum malaria in Thailand. Antimicrob Agents Chemother (2008) 2.23
Adverse effects in patients with acute falciparum malaria treated with artemisinin derivatives. Am J Trop Med Hyg (1999) 2.23
High-dose mefloquine in the treatment of multidrug-resistant falciparum malaria. J Infect Dis (1992) 2.21
Serology and carriage of Pseudomonas pseudomallei: a prospective study in 1000 hospitalized children in northeast Thailand. J Infect Dis (1993) 2.20
Comparative bioavailability of oral, rectal, and intramuscular artemether in healthy subjects: use of simultaneous measurement by high performance liquid chromatography and bioassay. Br J Clin Pharmacol (1996) 2.19
Efficacy and safety of dihydroartemisinin-piperaquine. Trans R Soc Trop Med Hyg (2007) 2.18
Population pharmacokinetics of mefloquine in patients with acute falciparum malaria. Clin Pharmacol Ther (1999) 2.16
Major pitfalls in the measurement of artemisinin derivatives in plasma in clinical studies. J Chromatogr B Analyt Technol Biomed Life Sci (2008) 2.16
Severe neurotoxic envenoming by the Malayan krait Bungarus candidus (Linnaeus): response to antivenom and anticholinesterase. Br Med J (Clin Res Ed) (1983) 2.15
Clinical pharmacokinetics of mefloquine. Clin Pharmacokinet (1990) 2.14
Intravenous quinidine for the treatment of severe falciparum malaria. Clinical and pharmacokinetic studies. N Engl J Med (1985) 2.12
Biochemical characteristics of clinical and environmental isolates of Burkholderia pseudomallei. J Med Microbiol (1996) 2.11
Treatment of vivax malaria on the western border of Thailand. Trans R Soc Trop Med Hyg (2000) 2.10
Comparison of imipenem and ceftazidime as therapy for severe melioidosis. Clin Infect Dis (1999) 2.10
Everest MS: Measurement of digoxin in plasma and its use in diagnosis of digoxin intoxication. Br Med J (1969) 2.08
Abnormal function of potassium channels in platelets of patients with Alzheimer's disease. Lancet (1998) 2.07
Validation and application of a liquid chromatographic-mass spectrometric method for determination of artesunate in pharmaceutical samples. J Pharm Biomed Anal (2007) 2.06
Natural history of recurrent urinary tract infections in women. Rev Infect Dis (1991) 2.05
Post-malaria neurological syndrome. Lancet (1996) 2.05
Systemic endothelial activation occurs in both mild and severe malaria. Correlating dermal microvascular endothelial cell phenotype and soluble cell adhesion molecules with disease severity. Am J Pathol (1998) 2.05